Ovarian Cancer

Sophia George, PhD, and Judith E. Hurley, MD, discuss the importance of the genetic association study, challenges faced with launching such an effort, the key findings from the research, and the clinical implications of the data in the Caribbean as well as the United States

Hye Sook Chon, MD, teases out some of the differences between the data with PARP inhibitors in the frontline maintenance setting and shed light on ongoing research with combinations that could broaden their utility in patients with advanced ovarian cancer.

Thomas C. Krivak, MD, discusses the significance of HRD in ovarian cancer, approved and prospective HRD tests, and considerations for genomic testing in this population.

John Nakayama, MD, discusses the potential utility of precision medicine with mirvetuximab soravtansine in ovarian cancer.

Eirwen M. Miller, MD, discusses her approach to frontline maintenance therapy in ovarian cancer.

Out-of-pocket costs for patients with ovarian cancer who have been treated with PARP inhibitors are generally low, according to recent study results from a single institution.

Digital media, now more than ever, has become a primary platform for communication, and in 2020, the production of the OncLive® podcast, OncLive On Air™, was put into overdrive to bring practicing oncologists exclusive biweekly interviews, discussions, and insights from leading experts in cancer care.

Robert Wenham, MD, MS, FACOG, FACS, discusses future directions with antibody-drug conjugates in the treatment of patients with ovarian cancer.

The combination of mirvetuximab soravtansine and rucaparib was found to be well tolerated, with encouraging activity reported in heavily pretreated patients with endometrial, ovarian, fallopian tube, or primary peritoneal cancer.

Dr. Coleman and Dr. Brown discuss how understandings of BRCA and patient eligibility for PARP inhibitors have evolved in ovarian cancer, the effects of frontline maintenance trials on treatment recommendations, the clinical significance of the findings from the ARIEL4 trial, and where PARP inhibition is headed in the field.

The addition of farletuzumab to carboplatin plus paclitaxel or carboplatin plus pegylated liposomal doxorubicin did not demonstrate superiority over placebo plus chemotherapy in patients with platinum-sensitive recurrent ovarian cancer who are in their first relapse and have low cancer antigen-125 levels.

The exploration of mirvetuximab soravtansine as a potentially efficacious treatment in patients with advanced, high-grade, platinum-resistant epithelial ovarian, primary peritoneal, or fallopian tube cancers with high folate receptor–alpha expression continues with the ongoing, single-arm, phase 3 SORAYA trial.

The GAS6/AXL inhibitor AVB-500, when combined with paclitaxel, elicited clinical benefit with favorable tolerability in patients with platinum-resistant ovarian cancer, according to data from a phase 1b study.

Jing-Yi Chern, MD, ScM, discusses the role of maintenance PARP inhibition in patients with recurrent platinum-sensitive ovarian cancer, as well as remaining questions regarding the utility of PARP inhibitors in this setting.

Olaparib, when used in patients with platinum-sensitive relapsed ovarian cancer who had a known BRCA mutation and homologous recombination deficiency status, demonstrated adverse effects that proved to be consistent with the established safety profile of the PARP inhibitor.

Maintenance niraparib demonstrated clinical benefit that persisted beyond first progression in patients with platinum-sensitive recurrent ovarian cancer with or without germline BRCA mutations.  

Maintenance olaparib showcased progression-free survival benefit in almost half of the patients with ovarian cancer vs 21% of those who received placebo, including consistent benefit in high- and low-risk patients.

Niraparib in combination with bevacizumab continued to showcase a progression-free survival benefit in patients with advanced ovarian cancer who previously received frontline platinum-based chemotherapy and bevacizumab.

Dostarlimab plus niraparib and bevacizumab showcased favorable antitumor activity and tolerability in patients with platinum-resistant ovarian cancer.

CA-125 surveillance alone could be used to detect disease progression in patients with advanced ovarian cancer and an abnormal CA-125 level at the beginning of frontline maintenance therapy with olaparib and bevacizumab, according to an analysis from the phase 3 PAOLA-1.

Rachel N. Grisham, MD, discusses the mechanism of action of VS-6766 in patients with recurrent low-grade serous ovarian cancer.

Sophia George, PhD, discusses actionable pathogenic variants in patients with breast cancer who live in the Caribbean.

In our exclusive interview, Dr. Monk and Dr. Herzog discuss the importance of molecular testing in ovarian cancer and the utility of PARP inhibitor maintenance and treatment.

Robert Wenham, MD, MS, FACOG, FACS, discusses the basis for combining chemotherapy, PARP inhibitors, and VEGF inhibitors with immunotherapy in ovarian cancer and ongoing research with ADCs in the field.

One in 7 Caribbean-born individuals with either breast or ovarian cancer had hereditary disease with an actionable pathogenic variant, which provides the opportunity for the utilization of targeted therapeutics and precise prevention strategies.